Longevity.Technology UNLOCKED

Longevity.Technology

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living.

🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem.
🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space.

If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

Play

Open in

34 episodes
a few times a week
Avg 37 min
English

Episodes 34

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Monday · 51 min
Could Intrinsic Capacity Become the Endpoint for Longevity Drugs?
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: John Beard Irene Diamond Professor and Director International Longevity Center USA, Columbia University LinkedIn: https://www.linkedin.com/in/john-beard-987b801b/ Website: https://www.publichealth.columbia.edu/profile/john-beard-mbbs ---------- What if the way we measure health is holding back the science of aging? Phil Newman sits down with Dr. John Beard, Irene Diamond Professor and Director of the International Longevity Centre USA at Columbia University, to explore intrinsic capacity – measuring health through what people can actually be and do rather than the diseases they have. Together they unpack the five domains of intrinsic capacity and why functional measures could give researchers a more continuous picture of aging. From simple chair-rise and hearing tests to clinical trial endpoints, biomarkers and wearables, Beard explains both the potential and the gaps that remain. They also discuss why “70 is the new 60,” the difference between prevention and health promotion, why some longevity clinics are ahead of the evidence, and how intrinsic capacity could reshape healthcare funding and drug development. In this episode, you'll learn: - Why disease alone is an incomplete measure of aging - How intrinsic capacity measures cognitive, locomotive, psychological, sensory and vitality domains - Why better standardized measures could help shorten aging intervention trials - How early-life health can influence capacity decades later - Why healthcare systems could eventually reward improvements in health rather than throughput If you want to understand how measuring function could change geroscience, clinical trials and healthcare itself, this episode connects aging biology with practical measures of how well people actually live. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
October 5 · 47 min
BPC-157, GLP-1s and the New Peptide Gold Rush
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: Fady Hannah-Shmouni, MD FRCPC Founder & CEO of Hormonaly.ai LinkedIn: https://www.linkedin.com/in/fady-hannah-shmouni/ Website: https://shmouni.com/ Koehl Robinson Founder & CEO of Celia Health LinkedIn: https://www.linkedin.com/in/koehlrobinson/ Website: https://www.celia-rx.com/ ---------- What happens when demand for peptide therapies starts moving faster than the science, regulation and clinical infrastructure surrounding them? Phil Newman sits down with Dr. Fady Hannah-Shmouni and Koehl Robinson to explore one of longevity medicine’s fastest-moving areas: peptides. From evidence-backed GLP-1 drugs to compounds such as BPC-157 with far more limited human evidence, they examine where the science is strong, where uncertainty remains and what patients should understand before entering this rapidly expanding market. Together they explore how a cleaner peptide supply chain could work, why testing and clinical oversight matter, and how real-world data could help fill some of the evidence gaps where randomized controlled trials remain limited. They also discuss personalized prescribing, biomarker monitoring, AI and what responsible peptide medicine could look like as the industry matures. In this episode, you'll learn: - Why Fady describes GLP-1s as the standout peptide class, with potential effects extending beyond weight management into appetite and other reward-related behaviors. - Why compounds such as BPC-157 still have major evidence gaps, with much of the published literature remaining preclinical rather than based on high-quality randomized human trials. - How Koehl says Celia RX is building a US-based supply chain with multiple stages of testing, third-party analysis and batch testing to improve transparency around peptide sourcing. - How lab, genomic and epigenetic testing could be combined with consultations and follow-up monitoring to move peptide prescribing toward a more personalized model. - Why AI and real-world multi-omic data could help clinicians make sense of a fragmented evidence base while researchers continue building stronger clinical evidence. The conversation also tackles the uncomfortable reality of the peptide “gray market.” As consumer demand grows, products can vary significantly in sourcing, testing and clinical oversight. Fady and Koehl discuss why transparency around evidence and risk matters, and why better infrastructure may be essential if peptide medicine is going to move further into mainstream healthcare. If you want to understand where peptide medicine stands today – from established therapies to experimental compounds – this episode separates the growing enthusiasm from the evidence still needed to support it. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
September 28 · 41 min
Are Your Supplements Actually Doing Anything?
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: Dr. Christopher Shade Founder and CEO of Quicksilver Scientific LinkedIn: https://www.linkedin.com/in/dr-christopher-shade-b5a44413/ Website: https://www.quicksilverscientific.com/ ---------- What if the biggest problem with your supplements isn’t what you take, but how much actually reaches your cells? Phil Newman sits down with Dr. Christopher Shade, founder and CEO of Quicksilver Scientific, to explore the science of supplement absorption, detoxification and next-generation nutrient delivery. Together they unpack why absorption can vary dramatically between compounds, how liposomal and nanoemulsion systems are designed to improve bioavailability, and why Shade believes detox requires more than short-term cleanses. From his “push-catch” approach to oral peptides, GLP-1 support and NAD+, the conversation examines how delivery could change the way longevity interventions are designed. In this episode, you'll learn: - Why Shade says detoxification needs to address cellular mobilization, liver and bile pathways, and elimination rather than relying on short-term “detox teas” or juice cleanses. - How absorption can vary dramatically between supplements, with Shade citing less than 1% absorption for standard berberine and reporting a 300-fold increase in curcumin absorption using his company’s delivery technology. - Why Quicksilver is exploring oral liposomal versions of peptides including BPC-157, KPV, TB-500, GHK-Cu and epitalin, and why Shade says dose equivalence matters when comparing oral delivery with injections. - Why coming off GLP-1 drugs may require more than simply stopping treatment, with nutrition, exercise and metabolic health forming part of the wider conversation. - How Shade sees the future moving toward personalized supplement stacks guided by biomarkers, genomics and individual response, rather than simply taking more products. The conversation also tackles the increasingly crowded supplement market and the challenge consumers face when trying to distinguish meaningful delivery science from marketing claims. Shade argues that pharmacokinetic data, manufacturing quality and measurable absorption should matter more than simply seeing “liposomal” written on a label. If you want to understand why longevity may depend not only on what you take, but whether your body can actually use it, this episode connects chemistry, supplementation and emerging delivery technologies with a more measured approach to optimizing health. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
September 25 · 27 min
Longevity Biotech’s $617Billion Opportunity | Longevity News Roundup — Week 39, 2026
Sponsored by: MuseCell Innovations MuseCell Innovations is the exclusive global licensor of Dezawa MuseCells®, a naturally occurring, pluripotent-like stem cell platform discovered by Professor Mari Dezawa at Tohoku University. Built on more than 15 years of peer-reviewed research, the company focuses on advancing regenerative medicine across longevity, disease treatment, performance and aesthetics through authenticated cell technology and licensed manufacturing methods. Read more about it here: https://bit.ly/4y0rhpW Free Report: https://longevity.technology/data/report/longevity-biotech-report-2026/ Market Model Explorer: https://longevity.technology/data/dashboard-biotech-explorer-tam-and-value/ ---------- In this special Longevity News Roundup, Phil Newman explores the findings behind Longevity.Technology’s latest Longevity Biotech Report, examining investment, market potential, regulation, global competition and regenerative platforms. - More than $30 billion has flowed into longevity biotech in under two years, with investment increasingly concentrated in larger deals and companies with credible clinical programmes. - The report forecasts a potential $617 billion annual global market by 2045, based on assumptions around pricing, population uptake, prevention and the emergence of new healthcare budgets. - The existing pipeline is already projected toward $230 billion in annual revenue through conventional disease indications, with a further $173 billion in potential gerotherapeutic upside if regulatory pathways develop. - Regulatory change could be critical, with ARPA-H’s PROSPR programme, biomarker qualification and future legislative frameworks potentially helping move ageing-related interventions toward multi-disease approval pathways. - China is becoming an increasingly important force, with 59 China-headquartered companies in the tracked cohort raising $16.9 billion and reportedly moving clinical programmes 50–70% faster than US counterparts. - Regenerative platforms such as MuseCell Innovations could offer a more scalable development model, allowing validated platforms to support multiple disease programmes while still requiring indication-specific clinical evidence and regulatory approval. News & References: - $617 billion longevity biotech market takes shape → https://longevity.technology/news/617-billion-longevity-biotech-market-takes-shape/ - What is longevity biotech really worth? → https://longevity.technology/news/what-is-longevity-biotech-really-worth/ - Longevity biotech’s 100x question → https://longevity.technology/news/longevity-biotechs-100x-question/ ---------- Host: Phil Newman: https://qrco.de/bgXpNY
September 21 · 48 min
Menopause Changes the Brain More Than We Realised
Sponsor: Sooo.me Sooo.me™ is a longevity-focused nutraceutical brand offering science-backed supplements designed to support healthy aging, energy, focus, cellular health, and overall wellbeing. Its range combines high-purity ingredients, medicinal mushroom extracts, and targeted formulations with an emphasis on quality, transparency, and sustainable packaging. See what it can do for you — click below to try it today and use code LONGEVITYTECHNO for 10% off. Link: https://sooo.me/?ref=LTUNLOCKED ---------- Guests: Elizabeth Poynor, MD, Ph.D Chair of Women's Health & Gynecology of Atria Health Institute LinkedIn: https://www.linkedin.com/in/elizabeth-poynor-md-phd-390491177/ Website: https://www.atria.org/doctors/ David Dodick, MD Chief Medical Officer of Atria Health Institute LinkedIn: https://www.linkedin.com/in/david-dodick-93a107269/ Website: https://www.atria.org/doctors/ ---------- What if protecting women’s brains from dementia needs to begin decades before symptoms appear? Phil Newman sits down with Dr. Elizabeth Poyner and Dr. David Dodick to explore why midlife should be viewed not simply as a reproductive transition, but as a major neurological, hormonal and cardiometabolic one. Together, they examine how fluctuating estrogen during perimenopause can influence brain energetics, sleep, memory and executive function – often before women even recognize they are approaching menopause. Together they explain how fluctuating estrogen can affect brain energetics, why migraine can signal hormonal change, and how insulin resistance, visceral fat and chronic stress can compound brain-health risks. They also unpack the critical window for hormone therapy and why prevention needs a personalized approach. In this episode, you'll learn: Why almost two out of every three Americans living with Alzheimer’s are women, and why longevity alone may not explain the difference. How estrogen fluctuations can affect glucose metabolism, mitochondrial function, sleep and cognitive performance during midlife. Why migraine affects women around three times more often than men and can worsen dramatically during perimenopause. Why optimizing 14 modifiable risk factors could prevent at least 45% of dementia, and why exercise may be one of the most powerful interventions available. How combining hormonal, neurological, metabolic and cardiovascular assessments could enable a more personalized approach to protecting women’s long-term brain health. If you want to understand women’s brain aging, this episode connects hormones, metabolism and neuroscience with practical insights for protecting long-term health. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
September 14 · 48 min
Can You Make Your Brain 5 Years Younger?
Guests: Paola Telfer Founder and CEO of Sens.ai LinkedIn: www.linkedin.com/in/paolatelfer/ Website: sens.ai/ Eric Verdin, MD President and CEO of the Buck Institute for Research on Aging LinkedIn: www.linkedin.com/in/eric-verdin-md/ Website: www.buckinstitute.org/ ---------- What if we could track brain aging through function, not just structure? Phil Newman sits down with Paola Telfer, founder and CEO of Sens.ai, and Eric Verdin, president and CEO of the Buck Institute for Research on Aging, to explore BrainYears™, a functional brain age clock designed to measure how the brain performs as it ages. Together they explain how 643 EEG, response and performance variables were analyzed using machine learning to build the BrainYears™ model. They discuss why brain function could complement MRI, retinal, proteomic and epigenetic clocks, and how data collected from people aged 13 to their late 80s helped build the model. The conversation also examines a reported 5.18-year reduction in BrainYears™ following a two-month intervention, while stressing that this early finding still requires prospective, placebo-controlled validation. They also explore neurofeedback, HRV biofeedback and transcranial photobiomodulation, the potential role of BrainYears™ in clinical practice, and Eric’s vision for a scientifically rigorous space between conventional medicine and consumer wellness. In this episode, you’ll learn: Why functional brain aging may be a missing dimension in current aging clocks How 643 EEG, response and performance variables were narrowed down using machine learning to create the BrainYears™ model Why tracking trajectory over time may be more informative than a single biological age score What the early intervention data showing a reported 5.18-year BrainYears™ reduction actually tells us Why future validation needs to compare BrainYears™ with MRI-based clocks, proteomics and other measures of brain aging If you want to understand how brain aging could become measurable, trackable and potentially modifiable earlier in life, this episode explores the science, technology and validation challenges shaping that future. Subscribe for weekly episodes exploring longevity science, preventative medicine and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
September 11 · 16 min
The Smart Ring Accuracy Crisis | Longevity News Roundup — Week 37, 2026
In this week’s Longevity News Roundup, Phil Newman examines Oura’s IPO and sleep suit, movement context in dementia, dog gene therapy, Rentosertib biological clocks, and women's health. ŌURA filed for a $16 billion IPO on Nasdaq under ticker Oura, seeking to raise up to $3 billion. Simultaneously, the smart ring company is defending its sleep stage tracking accuracy in a California class action lawsuit alleging its metrics are no better than a coin flip. A 74-study review of 4.2 million people showed leisure movement lowered dementia risk by 24%, while physically demanding jobs increased risk by 20%. This highlights how movement context and recovery matter far more than basic step counts. GenFlow Biosciences reported that its SLAB trial testing SIRT6 gene therapy in 24 aged beagles met its primary endpoint. Treated dogs demonstrated reduced biological age on the Grim methylation clock alongside secondary functional gains. Insilico Medicine published a Phase 2a trial analysis revealing its AI-designed IPF drug Rentosertib reduced predicted biological age. Across six proteomic clocks, patients taking 30 mg twice daily showed three to four years of age reduction. Biograph launched a dedicated women's preventative health program integrated into its concierge membership tiers. The program combines hormone testing, personalized risk assessments, and life-stage care spanning perimenopause, menopause, and cardiovascular health. ---------- News & References: ‘Biograph builds dedicated women’s preventive health arm → https://longevity.technology/news/biograph-builds-dedicated-womens-preventive-health-arm/ Rentosertib puts aging clocks to the clinical test → https://longevity.technology/news/rentosertib-puts-aging-clocks-to-the-clinical-test/ Genflow Biosciences trial meets primary endpoint in aged dogs → https://longevity.technology/news/genflow-biosciences-trial-meets-primary-endpoint-in-aged-dogs/ Study shows the way you move matters more than how often → https://longevity.technology/news/study-shows-the-way-you-move-matters-more-than-how-often/ Smart ring maker Oura prepares for US IPO at up to $3b raise → https://longevity.technology/news/smart-ring-maker-oura-prepares-for-u-s-ipo-at-up-to-3b-raise/ ŌURA defends its sleep science amid class-action lawsuit → https://longevity.technology/news/oura-defends-its-sleep-science-amid-class-action-lawsuit/ ---------- Host:Phil Newman: https://qrco.de/bgXpNY
September 7 · 17 min
Will AI Make Death Optional?
What would have to be true for AI to genuinely change the trajectory of human aging? The answer is more complicated than simply discovering an “anti-aging drug.” AI is already compressing parts of drug discovery, with one AI-designed candidate reaching Phase 2 trials in under 30 months, while new biological aging clocks could allow researchers to measure changes in months rather than decades. But aging is not a single disease. It involves interconnected processes including cellular senescence, mitochondrial dysfunction, immune changes, DNA damage, and loss of biological coordination. AI can search faster, but it cannot remove the underlying biological trade-offs or eliminate the need for long-term human safety data. Phil examines what longevity escape velocity actually means, why skepticism remains essential, and whether AI can accelerate progress quickly enough to matter within our own lifetimes. In this episode, you’ll learn: How AI is compressing drug discovery timelines and what that could mean for longevity research. Why biological aging clocks could become critical tools for testing interventions faster. Why aging is fundamentally more complex than targeting a single disease pathway. How cellular reprogramming illustrates both the promise and risks of manipulating aging biology. Why progression from Phase 1 to Phase 2 may be a more useful scorecard than predictions about longevity escape velocity. If you want to understand what AI can realistically change about the pace of longevity research, this episode connects faster drug discovery and biological aging measurement with the deeper challenges of intervening in a complex, interconnected aging process. It explores where the science is genuinely moving forward, where the biggest limitations remain, and what could determine whether today’s advances translate into meaningful healthspan gains. Subscribe for more Longevity Bites, where Phil Newman breaks down the science, ideas, and emerging technologies shaping the future of human longevity ---------- Host: Phil Newman: https://qrco.de/bgXpNY
September 4 · 17 min
The $820 Million Bet to Transform Hair Loss Treatment | Longevity News Roundup - Week 36, 2026
In this week’s Longevity News Roundup, Phil Newman examines the developments reshaping longevity and healthspan, from a major biotech investment in hair loss to AI-driven drug repurposing, the industry’s communication challenge, biological-age testing at population scale, and the push to manufacture regenerative cell therapies in the US. Veradermics has built an $820 million war chest to advance VDPHL01, an extended-release oral formulation of minoxidil for male and female pattern hair loss. Phase 3 data for men are expected in the second half of 2026, with topline results from the women’s Phase 2/3 trial expected in the first half of 2027. THPharm and Insilico Medicine are using AI to investigate new applications for THP-001, already in global Phase 3 trials. PandaOmics is analysing 16 datasets covering 269 samples to explore potential applications in heart failure, fatty liver disease and obesity. HEALTH’s new Longevity Insights Report, based on responses from 1,000 Americans, suggests consumers are more interested in staying healthy, energetic and independent than simply extending lifespan. Humanity and Quest Diagnostics are making biological-age analysis available through Quest’s direct-to-consumer testing platform for $29. The bigger opportunity may be turning biological age into a repeatable health metric that encourages prevention and measurable improvements over time. Celularity and MuseCell Innovations are establishing US manufacturing for Dezawa MuseCells, alongside derived products including MuseExosomes and MuseSecretome. The collaboration addresses one of regenerative medicine’s biggest challenges: producing specialist cell therapies consistently and at scale. News & References: ‘Veradermics builds $820m war chest for oral hair loss pill → https://longevity.technology/news/veradermics-builds-820m-war-chest-for-oral-hair-loss-pill/ AI hunts new uses for Phase 3 metabolic drug → https://longevity.technology/news/ai-hunts-new-uses-for-phase-3-metabolic-drug/ New survey reveals what Americans really want from longevity → https://longevity.technology/news/new-survey-reveals-what-americans-really-want-from-longevity/ Quest, Humanity bring biological age test to 2,000 US locations→ https://longevity.technology/news/quest-humanity-bring-biological-age-test-to-2000-us-locations/ Celularity, MuseCell Innovations to build US Dezawa MuseCell plant → https://longevity.technology/news/celularity-musecell-innovations-to-build-us-dezawa-musecell-plant/ ---------- Host:Phil Newman: https://qrco.de/bgXpNY
August 31 · 51 min
Are Longevity Clinics Actually Evidence-Based?
Guest: Joanna Bensz Founder & CEO of Longevity Center and Longevity Academy LinkedIn: https://www.linkedin.com/in/joanna-bensz-205b315/ Website: https://longevity-academy.com/, https://longevity-center.eu/ ---------- What happens when longevity becomes a global industry before the medical system has agreed on what good longevity medicine actually looks like? Phil Newman sits down with Joanna Bensz, entrepreneur, founder of the International Institute of Longevity, Longevity Academy and Round Table of Longevity Clinics, to explore how a rapidly expanding sector can develop credible standards while keeping pace with commercialization. They discuss the growth of longevity clinics, from premium destinations and telehealth platforms to sports centres and preventive health providers, and why Joanna estimates that only around 20% of the clinics she knows genuinely focus on diagnostics and interventions. The conversation examines peptides, biological-age testing, clinical education and the need for protocols that connect biomarkers with appropriate interventions rather than simply adding more treatments. Joanna explains how Longevity Academy evolved from an internal doctor-training programme into an educational platform for clinicians, drawing on real-world clinic experience, biomarkers, testing and treatment decisions. The episode goes beyond the clinic itself, examining the growing role of sports centres, retreats, AI, mental health, nervous-system regulation, nutrition and family health. Joanna argues that longevity should not be reduced to peptides or expensive interventions, but should include the everyday environments and behaviours that shape health across the lifespan. In this episode, you’ll learn: Why rapid commercialization could outpace the development of clinical standards Why Joanna estimates only around 20% of longevity clinics genuinely focus on diagnostics and interventions How Longevity Academy is helping doctors bridge gaps in conventional medical education Why peptides illustrate the regulatory differences between the US and Europe Why longevity clinics need doctors, nutritionists, psychologists, coaches and other specialists working together - How biomarkers can be used to track changes before and after interventions Ultimately, this episode asks whether longevity medicine can become a credible part of healthcare without losing scientific and clinical rigor as the market scales. For Joanna, the path forward involves better education, clearer standards, measurable outcomes, collaboration and a more integrated approach to health that extends beyond the traditional doctor-patient relationship. Subscribe for weekly episodes exploring longevity science, preventative medicine, healthcare innovation and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
August 24 · 38 min
The $51M Bet to Make the Doctor Obsolete
Sponsor: Longevity Investors Conference The Longevity Investors Conference brings together the scientists working at the root of aging, the clinicians translating research into practice, the founders building the next generation of longevity companies, and the investors deciding what gets funded next. The seventh edition takes place from 14 to 17 September 2026 at Le Grand Bellevue in Gstaad, Switzerland. Participation is limited and applications are reviewed individually. Click the link below to apply for LIC 2026. Link: https://www.longevityinvestors.ch/lic-2026 ---------- Guests: Max Marchione Founder & CEO of Superpower, Speaker at Longevity Investors Conference Gstaad 2026 LinkedIn and X: https://www.linkedin.com/in/maxmarchione/, https://x.com/maxmarchione Website: https://superpower.com/ ---------- What if the future of healthcare is not a better hospital, but a system designed to keep you out of one? Phil Newman sits down with Max Marchione, co-founder and CEO of Superpower, to explore his vision for a preventive health platform combining advanced diagnostics, longitudinal health data, wearables, AI and clinicians in one continuous system. Recorded as a Longevity Investors Conference special, the conversation examines why healthcare remains largely reactive and episodic, and what it would take to create an experience that continuously monitors health, connects biological signals and intervenes before problems become disease. Max explains how Superpower uses AI to examine data across blood tests, medical records and wearables, identifying patterns that may be difficult to uncover during a short medical appointment. They also discuss where human clinicians remain essential, particularly when decisions involve prescriptions, hormone therapy or other higher-risk interventions. The conversation explores the limitations of conventional blood-test reference ranges, the growing interest in peptides, including GLP-1 therapies and the controversial BPC-157, and why promising anecdotes must still be tested through rigorous clinical research. They also discuss Superpower’s direct-to-consumer and employer-funded models, the observational health dataset the company is building, the regulatory debate around right-to-try laws and Max’s much larger ambition to help create healthier cities. In this episode, you’ll learn: Why Max believes healthcare will become more preventive, continuous and software-driven.How AI could connect patterns across blood tests, wearables, medical records and reported symptoms.Why being within a “normal” blood-test range does not necessarily mean a result is optimal for long-term health. Where AI may support medical reasoning and why physicians remain responsible for important treatment decisions. How Superpower aims to make elements of high-cost concierge medicine accessible at a lower price. Why employers and insurers may have a financial incentive to invest in preventive healthcare. Why peptides could become an increasingly important medical modality, and where the evidence remains uncertain. How repeated testing, treatment data and symptom tracking could contribute to longitudinal observational research. What right-to-try laws could mean for medical autonomy, regulation and clinical innovation. What a health-first city might look like and why infrastructure, community and culture matter as much as policy. If you want to understand how AI, continuous diagnostics and longitudinal data could shift healthcare from episodic treatment toward proactive health management, this episode connects an ambitious technological vision with the clinical, commercial and regulatory realities of building a new healthcare system. Subscribe for weekly episodes exploring longevity science, preventive medicine and the systems shaping how we live longer and better. ---------- Host: Phil Newman: https://qrco.de/bgXpNY
August 21 · 16 min
From K-Beauty to K-Longevity: South Korea’s New Health Model | Longevity News Roundup - Week 34, 2026
In this week’s Longevity News Roundup, Phil Newman examines South Korea’s emerging health tourism model, Network Bio’s biological data platform, Utah’s growing longevity economy, GenBio AI’s virtual cell system, and Longevica’s push toward clinical translation. South Korea is attracting international patients with comprehensive preventive screening that can combine bloodwork, imaging, cardiovascular assessment, cancer screening and physician consultation in a highly compressed pathway. Network Bio has launched with $50 million in financing, using patient tissue, paired blood samples, molecular data and longitudinal outcomes to search for biological signals that transfer across diseases. Utah is building a different kind of longevity hub, with physician-led practices, fitness and recovery businesses, diagnostics, consumer health brands and wellness companies clustering around Salt Lake City and Park City. GenBio AI has launched AIDO Cell, a stateful virtual cell designed to connect DNA, RNA, proteins and cellular behavior while retaining the effects of previous interventions. Longevica Therapeutics has appointed Dr. Prasun Mishra as CEO, bringing Genentech, Roche and NIH experience into a company attempting to move large-scale mammalian longevity research toward drug development. ---------- News & References: ‘The barriers aren’t clinical, they’re structural’ → https://longevity.technology/news/the-barriers-arent-clinical-theyre-structural/ Network Bio launches with $50m for biological AI → https://longevity.technology/news/network-bio-launches-with-50m-for-biological-ai/ Utah is building America’s longevity capital → https://longevity.technology/news/utah-is-building-americas-longevity-capital/ Can AI put the cell back together? → https://longevity.technology/news/can-ai-put-the-cell-back-together/ Longevica appoints ex-Genentech biotech veteran as CEO → https://longevity.technology/news/longevica-appoints-ex-genentech-biotech-veteran-as-ceo/ ---------- Host: Phil Newman: https://qrco.de/bgXpNY
August 17 · 33 min
The Longevity Tests That Actually Matter
Hosts: Phil Newman: ⁠qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠qrco.de/bgXpKn⁠ ---------- Sponsor: YEARS YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics, biomarkers, imaging, and longitudinal data, YEARS helps identify health risks earlier and build personalized strategies designed to support healthier, longer lives. Link: www.years.co/en ---------- Guests: Jürgen Mehrtens Co-Founder & CEO of YEARS LinkedIn: www.linkedin.com/in/j%C3%BCrgen-mehrtens-116303b1/ Website: www.years.co/en Alexandru Ardelean, MD Specialist in Internal Medicine of YEARS LinkedIn: www.linkedin.com/in/alexandru-c-ardelean-md-aba522109/ Website: www.years.co/en ---------- What if the future of preventive medicine is not simply better treatment, but knowing what is changing in the body years before disease appears? Phil Newman and Dr. Nina Patrick sit down with Dr. Alexandru Ardelean, internal medicine specialist at YEARS, and Jürgen Mehrtens, CEO of YEARS, to explore how predictive biomarkers and longitudinal health data could reshape the way we understand aging and prevention. Together they unpack the growing role of biomarkers such as GDF-15 and P-tau217. GDF-15 can reflect processes including mitochondrial dysfunction, hypoxia, oxidative stress, and chronic inflammation, while longitudinal measurements may reveal patterns that a single test cannot. They also discuss why these biomarkers are not yet used to prescribe specific treatments, but can help measure whether lifestyle interventions are working. The conversation also explores how YEARS is building a standardized longitudinal dataset by requiring clients to undergo the same diagnostic framework over time, creating data that could eventually help researchers and pharmaceutical companies better understand aging. They discuss biomarker variability, false negatives, patient adherence, community-based interventions, the role of partner gyms, YEARS' upcoming app, and the potential for private preventive medicine models to influence broader healthcare systems. In this episode, you’ll learn: Why GDF-15 is emerging as a marker of cellular stress and how it relates to mitochondrial dysfunction, oxidative stress, hypoxia, and chronic inflammation. Why P-tau217 and other predictive biomarkers still require careful interpretation, longitudinal measurement, and clinical context before they can guide primary prevention. How YEARS is building longitudinal datasets through standardized diagnostics repeated annually or every two years. Why lifestyle interventions remain the foundation of prevention, even as increasingly sophisticated biomarkers become available. How community events, partner gyms, and digital monitoring can help patients stay engaged between clinical visits. If you want to understand how predictive biomarkers could move healthcare from reacting to disease toward continuously measuring and managing risk, this episode connects emerging biomarker science with the practical realities of preventive medicine, patient behavior, and the future of longevity clinics. Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping how we live longer and better.
August 15 · 19 min
The Longevity Industry Is Building Its Own Rules | Longevity News Roundup - Week 33, 2026
Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week’s Longevity News Roundup, Phil Newman examines how longevity is developing the clinical standards, biological models and infrastructure needed to move from promising technology toward real-world medicine. Viome’s acquisition of Circulate Health brings therapeutic plasma exchange into a platform built around diagnostics, nutrition and coaching. Circulate’s network spans more than 200 partner clinics, creating a “measure, act, remeasure” model, while recent data on microplastics and biological age highlight the gap between measurable changes and proven healthspan outcomes. Longevity Clinics World and the Healthy Longevity Medicine Society have signed an MOU focused on evidence-based medicine, shared terminology, education, quality improvement and standardization. The collaboration also emphasizes that future accreditation must have separate governance and independent oversight. Kailera Therapeutics reported an active IND for ribupatide oral, with initiation of global Phase 3 obesity trials planned for the first half of 2027, and says its ribupatide injection Phase 2b high-dose obesity trial is fully enrolled with data anticipated in mid-2027; global Phase 3 KaiNETIC enrollment is on track for more than 4,700 participants with data expected in 2028. Immorta Bio proposes combining multi-omics, AI, digital twins and secure patient-owned data into a continuously learning precision-medicine system. Exploratory metabolomic data from more than 2,000 individuals identified nine metabolites associated with age. Insilico Medicine is developing its Virtual Aging Cell platform to model biological change across six interconnected scales, making biological age a core variable rather than simply an output. The key question is whether these simulations can generate predictions that survive experimental and clinical validation. ---------- News & References: Virtual cells learn to grow old → longevity.technology/news/virtual-cells-learn-to-grow-old/ Immorta Bio maps out AI’s next move in longevity → longevity.technology/news/immorta-bio-maps-out-ais-next-move-in-longevity/ Kailera Therapeutics reports Q2 2026 results, updates progress on obesity trials → longevity.technology/news/kailera-therapeutics-reports-q2-2026-results-updates-progress-on-obesity-trials/ HLMS and Longevity Clinics World join forces on standards → longevity.technology/news/hlms-and-longevity-clinics-world-join-forces-on-standards/ Is blood filtering the new wellness flex? → longevity.technology/news/is-blood-filtering-the-new-wellness-flex/ ---------- Hosts: Phil Newman: https://qrco.de/bgXpNY
August 10 · 1 hr 3 min
Are GLP-1 Drugs Costing You Muscle? The Truth About Protein & Weight Loss
Hosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn ⁠---------- Sponsor: YEARS YEARS is a physician-led longevity clinic in Berlin that takes a proactive approach to health. Combining advanced diagnostics, biomarkers, imaging, and longitudinal data, YEARS helps identify health risks earlier and build personalized strategies designed to support healthier, longer lives. Link: www.years.co/en ---------- Guest: Tom Rifai MD FACP DipABLM Founder and CEO at Reality Meets Science® LinkedIn: www.linkedin.com/in/flex5/ Website: realitymeetsscience.com/ Cristopher Gardner, PhD Professor of Medicine and Director at Stanford Nutrition Studies Research Group LinkedIn: www.linkedin.com/in/christopher-gardner-phd/ Website: med.stanford.edu/profiles/christopher-gardner Stuart Phillips, PhD Professor; Director, PACE and Professor, Kinesiology, Faculty of Science at McMaster University LinkedIn: www.linkedin.com/in/stuartmphillips/ Website: mira.mcmaster.ca/our-faculty/stuart-phillips/ ---------- What if the biggest advances in longevity have less to do with finding the perfect diet, and more to do with preserving muscle, improving movement, and building habits that last? Phil Newman and Dr. Nina Patrick sit down with Dr. Christopher Gardner, Professor of Medicine at Stanford University and one of the world's leading nutrition researchers, Dr. Stuart Phillips, internationally recognized expert in skeletal muscle, aging, exercise, and protein metabolism, and Dr. Tom Rifai, lifestyle medicine physician and nutrition specialist, to separate nutrition science from social media hype. Together they unpack why popular diet labels often distract from what truly matters, why muscle is emerging as one of the most important predictors of healthy aging, and how exercise, dietary quality, and sustainable behavior change consistently outperform quick fixes. From Mediterranean and vegan diets producing remarkably similar health outcomes when built around whole foods, to the growing challenges of preserving muscle during GLP-1 driven weight loss, the discussion highlights where the evidence is strongest and where public perception has drifted away from the science. The panel also explores whether most people really need more protein, why resistance training matters far more than simply increasing protein intake, how clinicians should approach muscle preservation in older adults, and why food policy, environment, and long-term coaching may ultimately have a greater impact on population health than the latest nutrition trend. In this episode, you’ll learn: Why the quality of your diet matters far more than choosing keto, vegan, carnivore, or Mediterranean How skeletal muscle supports mobility, glucose regulation, metabolic health, and healthy aging What current evidence actually says about protein requirements for longevity and muscle maintenance Why GLP-1 medications should ideally be paired with resistance training, nutrition guidance, and lifestyle support How small, sustainable behavior changes consistently outperform restrictive diets and short-term fixes Why whole foods, vegetables, legumes, and minimally processed diets remain the strongest common ground across nutrition research Whether you're trying to make sense of conflicting nutrition advice, optimize healthy aging, or understand where longevity science is actually headed, this conversation brings together decades of clinical research, practical medicine, and real-world experience to reveal the bigger picture. Subscribe for weekly conversations exploring longevity science, preventative medicine, biotechnology, and the innovations shaping how we live longer, healthier lives.
August 7 · 13 min
Why Women May Need a Completely Different Longevity Playbook | Longevity News Roundup—Week 32, 2026
Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman explores whether aging research has overlooked half the population, why supplement quality is becoming a scientific issue, how NAD+ science is moving into pharmaceutical development, and what superagers reveal about the limits of genetic prediction. A new $7.5 million NIH-funded center at USC will investigate sex differences in aging after decades of male-biased research. The initiative could reshape biomarkers, clinical trials, and personalized longevity interventions. Swiss longevity company Timeline won a $5.3 million judgment against sellers falsely marketing products as containing urolithin A. The ruling reinforces that scientific evidence depends on products containing the same ingredient and dose used in clinical research. Niagen Bioscience has partnered with Evotec to advance NB4168, an oral NAD+ small molecule for a rare pediatric neurodegenerative disease. The collaboration highlights how longevity companies are increasingly translating supplement science into regulated drug development. Researchers found that superagers shared similar Alzheimer's genetic risk profiles with cognitively average older adults. Rather than supporting a DNA destiny narrative, the findings point toward resilience mechanisms that future studies will explore through biomarkers, immune profiling, brain imaging, and lifestyle. ---------- News & References: What if aging research has been studying the wrong sex? → https://longevity.technology/news/what-if-aging-research-has-been-studying-the-wrong-sex/ Timeline wins $5.3m in fake urolithin A case → https://longevity.technology/news/timeline-wins-5-3m-in-fake-urolithin-a-case/ Niagen Bioscience teams up with Evotec to prepare rare disease drug for human trials → https://longevity.technology/news/niagen-bioscience-teams-up-with-evotec-to-prepare-rare-disease-drug-for-human-trials/ SuperAgers challenge the DNA destiny narrative → https://longevity.technology/news/superagers-challenge-the-dna-destiny-narrative/ ---------- Hosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠
August 3 · 47 min
Why “Normal” Blood Results Could Be Misleading
Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: www.getstride.com/unlocked/ ---------- Guest: Andrew Steele Co-Founder & CEO of Stride LinkedIn: www.linkedin.com/in/andrewsteeleathlete/ Website: www.getstride.com/eu/ ---------- What if the future of healthcare isn't about finding disease earlier, but preventing it from developing in the first place? Phil Newman and Dr. Nina Patrick sit down with Andrew Steele, founder and CEO of Stride and former Olympic sprinter, to explore how personalized health is evolving beyond wearables, blood tests, and genetic reports into a truly integrated model of prevention. Drawing on his experience as an elite athlete and entrepreneur, Andrew explains why collecting more health data isn't enough, and why the real challenge is helping people make better decisions that actually change long term behavior. The conversation explores how Stride combines genetics, microbiome testing, advanced blood biomarkers, wearable data, and practitioner coaching into a single preventive health platform designed to prioritize the actions that matter most. Rather than overwhelming people with hundreds of recommendations, Andrew argues that sustainable health improvement comes from identifying a few highly personalized interventions that create momentum for broader lifestyle change. They also discuss how longitudinal testing can reveal patterns that traditional healthcare often misses. Instead of relying on whether a biomarker sits inside or outside a population reference range, Andrew explains why understanding an individual's direction of travel over time may provide much earlier signals of future health risks. The discussion explores how integrating multiple biological data layers could eventually allow AI powered systems to identify preclinical risk years before disease develops. The episode also examines the growing role of consumer health technologies, the limitations of existing healthcare systems, and why prevention increasingly sits outside traditional medicine. Andrew shares why he believes younger generations are embracing longevity as part of their identity, how behavioral psychology influences successful health interventions, and why human coaching remains essential even in an AI driven future. In this episode, you’ll learn: Why personalized health requires more than DNA tests or wearable devices How combining genetics, microbiome data, blood biomarkers, and lifestyle creates a more complete picture of health Why focusing on three meaningful actions is more effective than dozens of recommendations How longitudinal biomarker tracking may detect risk before conventional clinical thresholds are reached Why AI works best when combined with experienced healthcare practitioners If you want to understand where personalized medicine is heading, how AI could transform prevention, and why the next generation of healthcare may be built around continuous, individualized guidance rather than reactive treatment, this episode offers an insightful look at the future of longevity. Subscribe for weekly conversations exploring longevity science, precision medicine, biotechnology, AI, and the innovations shaping healthier, longer lives.
July 31 · 30 min
One-Shot Gene Therapies & Peptides | Longevity News Roundup—Week 31, 2026
Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy. Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach. An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials. Vandria announced that its oral mitochondrial therapy VNA-318 safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials. Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation. D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss. Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies ---------- News & References: Voyager’s single-dose gene therapy cuts tau by 75% → https://longevity.technology/news/voyagers-single-dose-gene-therapy-cuts-tau-by-75/ FDA panel backs peptides over its own scientists → https://longevity.technology/news/fda-panel-backs-peptides-over-its-own-scientists/ Vandria’s experimental Alzheimer’s pill proves safe, reaches target in first human study → https://longevity.technology/news/vandrias-experimental-alzheimers-pill-proves-safe-reaches-target-in-first-human-study/ Montana takes next step on experimental therapies → https://longevity.technology/news/montana-takes-next-step-on-experimental-therapies/ Zabopegdutide shows rapid, weight-independent liver benefits in Phase 2 → https://longevity.technology/news/zabopegdutide-shows-rapid-weight-independent-liver-benefits-in-phase-2/ Genflow reports positive early results in aging-dog gene therapy trial → https://longevity.technology/news/genflow-reports-positive-early-results-in-aging-dog-gene-therapy-trial/
July 27 · 48 min
Can Longevity Become Public Policy?
Hosts: Phil Newman: ⁠https://qrco.de/bgXpNY⁠ Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠ ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: ⁠rechargehealthas.sjv.io/jRQyQ5⁠ ---------- Guests: Dylan V. Livingston Founder and CEO of The Alliance for Longevity Initiatives (A4LI) LinkedIn: ⁠www.linkedin.com/in/dylan-v-livingston/⁠ Website: ⁠a4li.org/⁠ ---------- What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy? In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging. Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice. The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials. They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine. In this episode, you’ll learn: Why public policy may become the biggest accelerator, or bottleneck, for longevity science. How a proposed multi-disease therapeutic designation could speed the development of aging interventions.- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways. How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data. Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare. If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come. Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.
July 24 · 28 min
The First Real Longevity Drugs Are Getting Closer | Longevity News Roundup – Week 30, 2026
Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: https://rechargehealthas.sjv.io/jRQyQ5 ---------- In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health. Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study. Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration. Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry. Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures. Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing. ---------- News & References: Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/ Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/ Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/ Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/ Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/

Showing 1–20 of 34 episodes